Amiodarone-associated granuloma in bone marrow.
BACKGROUND
Amiodarone hydrochloride is classified as a Vaughan Williams class III antiarrhythmic agent, although class I, II, and IV effects may contribute to its favorable antiarrhythmic profile. It is associated with a wide variety of adverse effects, such as hypothyroidism, hyperthyroidism, interstitial pulmonary disease, hepatitis, coagulation disorders, skin photosensitivity, corneal microdeposits, alopecia, peripheral neuropathy, and cardiovascular arrhythmias.


METHODS
Bone marrow aspirations and biopsies were performed on two patients treated with amiodarone, on the first during a follow-up for myelofibrosis and on the second for a suspected lymphoproliferative disorder. Several bone marrow granulomas were found in both patients. The bone marrow specimens for tuberculosis and fungal stains were negative.


CONCLUSIONS
The temporal relationship between the amoidarone therapy and the development of two cases of asymptomatic bone marrow granuloma suggest the possibility that this antiarrhythmic agent is involved in the etiology of these granulomas.
Rosenbaum
H
H
Department of Hematology, Rambam Medical Center, B Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Ben-Arie
Y
Y
Azzam
Z S
ZS
Krivoy
N
N
D000368:Aged; D000638:Amiodarone / Q000009:adverse effects* / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001855:Bone Marrow Diseases / Q000139:chemically induced*; D005260:Female; D006099:Granuloma / Q000139:chemically induced*; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000188:drug therapy; D008875:Middle Aged; D055728:Primary Myelofibrosis / Q000188:drug therapy
D000889:Anti-Arrhythmia Agents; D000638:Amiodarone